Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals is a Shenzhen-listed (SZSE: 002294) company with a cardiovascular focus. Its triple-combination tablet of sacubitril, allisartan and amlodipine had its NDA accepted in China in July 2026, following Phase 3 SALUS data presented at ESC 2026.
| Headquarters | Shenzhen, China |
|---|---|
| Listing | SZSE:002294 |
| Lead asset / stage | sacubitril/allisartan calcium/amlodipine tablets NDA accepted — China |
| Latest event | Salubris reported presentation of Phase 3 SALUS clinical data at ESC 2026. |